Alvogen
Focus: Alvogen is a generics and OTC manufacturer headquartered in Morristown, NJ, publicly traded with a diversified portfolio across oncology, hematology, and chronic disease areas. The company derives 25% of revenue from Exemestane, a post-LOE aromatase inhibitor for breast cancer.
Profile data last refreshed 1m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
9-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Alvogen?
AI assessmentAlvogen offers stability in the generics sector and pipeline diversification, but minimal current hiring and heavy LOE exposure create limited near-term advancement opportunities.
Why Work Here
- Established public generics platform with diverse therapeutic focus spanning oncology, hematology, immunology, endocrinology, and cardiovascular indications
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
12 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$8M Part DStable
Post-LOE
Represents 25% of company revenue; irreversible aromatase inactivator for hormone-dependent breast cancer.
Help build intelligence for Alvogen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.